Haystack MRD® receives New York State approval

Meet us at San Antonio Breast Cancer Symposium 2026

Join us at the 2026 San Antonio Breast Cancer Symposium (SABCS) as we share how Quest Diagnostics can operationalize your precision oncology vision for breast cancer care:

  • Comprehensive test menu covering screening, pathology, and solid tumors
  • Broad coverage for enhanced access—in network for >90% of lives nationwide.
  • Unmatched patient access—no other company provides a comprehensive test menu and national infrastructure of more than 2,400 Patient Service Centers, plus in-office services and mobile phlebotomy
  • Advanced testing that’s affordable—flexible and easy-to-use financial assistance program
  • Dedicated oncology support for providers—Oncology Service Excellence as dedicated client service (1.833.710.0351)

MRD assays are not interchangeable, and treatment decisions shouldn’t be made as if they were

At Quest Diagnostics booth #1532, you’ll learn what sets Haystack MRD apart:

  • Zero false positives have been observed in published clinical studies to date,1-3 giving you the confidence to act
  • The highly optimized evolution of the chemistry employed in the DYNAMIC study4-5
  • Combination of ultrasensitive detection (validated 95% limit of detection at 0.0006% tumor fraction) to catch the lowest levels of disease with exceptional specificity
  • Proprietary dual-strand error correction that double-checks each variant to eliminate sequencing noise

Based on technology built by pioneers of cancer genomics, Haystack MRD empowers clinicians with exceptional clarity in clinical decision-making.

See 3 poster presentations featuring Haystack technology

We are proud to collaborate with clinical researchers who will present 3 research posters at SABCS this year featuring Haystack technology. Whether you’re a clinician navigating complex treatment decisions or a biopharma leader driving trial innovation, Haystack MRD brings sensitivity, specificity, and scale to breast cancer treatment monitoring.

Circulating tumor DNA (ctDNA) dynamics in early-stage triple-negative breast cancer: an early analysis of the phase II OCTANE trial

Abstract number: 2467
Presentation number: P1-5-03
Date/time: Wednesday, December 9, 2026, 12:30 PM–2:00 PM
Session: Poster Session 1
Presenter: Mridula George of Rutgers Cancer Institute, New Brunswick, N

Longitudinal ctDNA analysis for metastatic recurrence monitoring in low-risk HR+/HER2− early breast cancer

Abstract number: 2558
Presentation number: P1-9-15
Date/time: Wednesday, December 9, 2026, 12:30 PM–2:00 PM
Session: Poster Session 1
Presenter: Dae-Won Lee of Memorial Sloan Kettering Cancer Institute, New York, NY

Immune targeting of the ESR1 receptor as shared neoantigen for treatment or prevention of estrogen receptor positive breast cancer

Abstract number: 2689
Presentation number: P4-14-14
Date/time: Thursday, December 10, 2026, 5:00 PM–6:30 PM
Session: Poster Session 4
Presenter: Aixa E Soyano, Moffitt Cancer Center, Tampa, FL

Let’s connect in San Antonio


References
  1. Clark M, Prathapam R, Bramlett KS, et al. Highly accurate detection of circulating tumor DNA for monitoring minimal residual disease in solid tumors: analytical and clinical validation of the haystack MRD assay. J Mol Diagn. doi:10.1016/j.jmoldx.2026.07.006
  2. Cercek A, Foote MB, Rousseau B, et al. Nonoperative management of mismatch repair–deficient tumors. N Engl J Med. 2025;392(23):2297-2308. doi:10.1056/NEJMoa2404512
  3. Winters HD, Nguyen TJ, Suresh R, et al. Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). J Clin Oncol. 2026;44(2_suppl):30-30. doi:10.1200/jco.2026.44.2_suppl.30
  4. Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075
  5. Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. doi:10.1038/s41591-025-03579-w

Subscribe for updates

No spam, notifications only about new products, updates.
News and events

Meet us at ESMO 2026

Visit the Quest Diagnostics booth #8002 | 23-27 October | Madrid, Spain
Join us at the 2026 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, the highly optimized evolution of the chemistry employed in

Follow us on social media

Complete the form for instant access

Download the whitepaper

Patient access application mailing instructions

Haystack MRD
C/O Quest Diagnostics
2501 S State Hwy 121, Suite 1100
Lewisville, TX 75067

Para solicitar ayuda financiera, complete la solicitud y firme la autocertificación.

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.